Tesamorelin
- Generic Name
- Tesamorelin
- Brand Names
- Egrifta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 218949-48-5
- Unique Ingredient Identifier
- MQG94M5EEO
- Background
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretr...
- Indication
Tesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
- Associated Conditions
- Lipodystrophies
- Associated Therapies
- -
Effects of Growth Hormone Releasing Hormone in HIV
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT01263717
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
- Conditions
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Theratechnologies
- Target Recruit Count
- 263
- Registration Number
- NCT00608023
- Locations
- 🇺🇸
Somero, Michael, Indio, California, United States
🇺🇸Office of Dr. Michael Somero, Palm Springs, California, United States
🇺🇸AIDS Research Alliance, West Hollywood, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.